Validating the effects of drug treatment on blood pressure in the General Practice Research Database

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 6, 2008, Pages 535-545

  Delaney, Joseph A C ^a,b,c   Moodie, Erica E M ^a   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Blood pressure; General Practice Research Database (GPRD); Linear mixed models; Multiple imputation; Random effects

Indexed keywords

CELECOXIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; WARFARIN; ANTIINFLAMMATORY AGENT;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CLINICAL RESEARCH; DATA BASE; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; ADULT; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; FACTUAL DATABASE; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; STATISTICAL ANALYSIS; STATISTICAL MODEL; TIME; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BLOOD PRESSURE; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LINEAR MODELS; LONGITUDINAL STUDIES; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PROTON PUMP INHIBITORS; TIME FACTORS; WARFARIN;

EID: 46349088681     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1553     Document Type: Article

References (32)

1. Marmot M, Elliott P. Coronary Heart Disease Epidemiology: From Aetiology to Public Health, 2nd edn. Oxford University Press: Oxford, 2005; 153-173.
2. Heitjan DF, Landis JR. Assessing secular trends in blood pressure: a multiple-imputation approach. J Am Stat Assoc 1994; 89(427): 750-759.
3. Cook NR. An imputation method for non-ignorable missing data in studies of blood pressure. Stat Med 1997; 16(23): 2713-2728.
4. Cook NR. Imputation strategies for blood pressure data non-ignorably missing due to medication use. Clin Trials 2006; 3(5): 411-420.
5. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18(6): 681-694.
6. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H. Validity of the general practice research database. Pharmacotherapy 2003; 23(5): 686-689.
7. Delaney JA, Opatrny L, Brophy JM, Suissa S. Interactions between anti-thrombotic drugs and the risk of gastro-intestinal haemorrhage. CMAJ 2007; 177(4): 347-351.
8. Krishnan S, Chawla N, Ezekowitz MD, Peixoto AJ. Warfarin therapy and systolic hypertension in men with atrial fibrillation. Am J Hypertens 2005; 18(12 Pt l): 1592-1599.
9. Lange S, Freitag G. Choice of delta: requirements and reality-results of a systematic review. Biom J 2005; 47(1): 12-27.
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158(9): 915-920.
11. Gelman A, Hill J. Data Analysis Using Regression and Multi-level/ Hierarchical Models. Cambridge University Press: New York, 2007.
12. Diggle PJ. An approach to the analysis of repeated measurements. Biometrics 1988; 44(4): 959-971.
13. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38(4): 963-974.
14. Little RJ. Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc 1995; 90(431): 1112-1121.
15. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168(1): 49-53.
16. Harris AD, McGregor JC, Perencevich EN, et al. The use and interpretation of quasi-experimental studies in medical informatics. J Am Med Inform Assoc 2006; 13(1): 16-23.
17. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995; 142(12): 1255-1264.
18. Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc 1996; 91: 473-489.
19. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods 2002; 7(2): 147-177.
20. Meng XL. Multiple-imputation inferences with uncongenial sources of input (with discussion). Stat Sci 1994; 10: 538-573.
21. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
22. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007; 16(3): 241-249.
23. Abrahamowicz M, MacKenzie T, Esdaile JM. Time-dependent hazard ratio: modeling and hypothesis testing with application in lupus nephritis. J Am Stat Assoc 1996; 91(436): 1432-1439.
24. Abrahamowicz M, MacKenzie TA. Joint estimation of time-dependent and non-linear effects of continuous covariates on survival. Stat Med 2007; 26(2): 392-408.
25. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? a meta-analysis of randomized, controlled trials. Hypertension 2007; 49(4): 792-798.
26. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165(5): 490-496.
27. Ray WA. Observational studies of drugs and mortality. N Engl J Med 2005; 353(22): 2319-2321.
28. Moodie EE, Richardson TS, Stephens DA. Demystifying optimal dynamic treatment regimes. Biometrics 2007; 63(2): 447-455.
29. Hernán MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15: 615-625.
30. Robins J. The control of confounding by intermediate variables. Stat Med 1989; 8: 679-701.
31. Schneeweiss S. Methods in pharmacoepidemiology: time-varying drug effects revisited. Pharmacoepidemiol Drug Saf 2006; 15(2): 93-94.
32. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemioiogy research. Pharmacoepidemiol Drug Saf 2007; 16(4): 393-401.